Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
In the March 2018 edition of the Hardman Monthly Newsletter, Nigel Hawkins addresses the attractions of quoted infrastructure funds that maintain a low profile. Over the next decade, infrastructure investment levels will remain high, especially in the energy, utilities and railways sectors. As such, infrastructure funds are well-placed to benefit from this trend. These funds, three of which are valued by the market at over £2bn, have been resilient performers over the last five years, althou...
Collagen Solutions is a biomaterials company developing and manufacturing medical grade collagen components for use in medical devices, research and regenerative medicine. A number of investment initiatives have been introduced to accelerate the rate of growth, including global commercial infrastructure and development of a pipeline of finished medical devices, the first of which will be ChondroMimetic for repair of small cartilage lesions. Eight years after implantation, clinical outcomes with ...
Collagen Solutions is a biomaterials company developing and manufacturing medical grade collagen components for use in medical devices, research, and regenerative medicine. A number of investment initiatives have been introduced to accelerate the rate of growth, including global commercial infrastructure and development of a pipeline of finished medical devices, the first of which will be ChondroMimetic for repair of small cartilage lesions. Although considerable progress has been made, recent r...
Collagen Solutions is a biomaterials company developing and manufacturing medical grade collagen components for use in medical devices, research, and regenerative medicine. A number of investment initiatives have been introduced recently to accelerate the rate of growth, including global commercial infrastructure and development of a pipeline of finished medical devices, the first of which will be ChondroMimetic for repair of small cartilage lesions. Recent results have highlighted the progress ...
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
​First half results to 30th September demonstrate clear progress against the Board’s objective of creating a business with at least a £100m valuation by 2020. Proforma sales growth of 97%, driven by new customer contract wins and by pipeline progress from existing customers’ medical device programmes. The potential for operations in China (via joint venture) and the development of a new production facility for a global device manufacturer are both in late stage discussions which would und...
​Collagen Solutions is a biomaterials company developing and manufacturing medical grade collagen components for use in medical devices, regenerative medicine, and in vitro diagnostic products. It supplies value-added bio-functional collagen, provides R&D and contract manufacturing services to a broad range of clients, ranging from research organisations to multi-national corporates and, with this acquisition, now has the option of selling a regenerative medical product into the orthobiologics...
Collagen Solutions announced that, together with The Electrospinning Company (private UK-based company), it has been selected as part of an Innovate UK grant award to develop a novel bio-synthetic surgical mesh for internal wound healing. Whilst of little financial relevance in the short term it illustrates the value and diversity of Collagen SolutionsÂ’ technology and provides another example of the route to realising longer term commercial opportunities.
The pre-year end trading update indicated a shortfall in sales of c.£0.36m for FY15, which is expected to impact EBITDA by c.£0.26m; attributed to customer specific issues which are not anticipated to impact the long term outlook for the Group. New client wins, however, in the past quarter illustrate the industry’s recognition of the Company’s product offering and technology. Moreover, the Company has yet to see the benefits of upselling opportunities from the SLB acquisition.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.